Danaher Corp
Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –
Danaher Cepheid Respiratory Testing Revenue by Year
Cepheid Respiratory Testing Revenue (GeneXpert 4-in-1 & COVID-19) ($M)
Danaher Cepheid Respiratory Testing Revenue: $1,900M in FY2025.
Where the FY2025 figure comes from
Source: Danaher IR — nongaap_2026Q3 ↗
Revenue from respiratory test cartridges run on the GeneXpert system (4-in-1 Flu A/B, RSV, SARS-CoV-2 combo and standalone COVID-19 tests); reported continuously across 15 consecutive quarters from Q1 2023 through Q3 2026 ($350M in Q3 2026; $1,900M for full-year FY2025).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cepheid Respiratory Testing Revenue (GeneXpert 4-in-1 & COVID-19) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,900 | – | Danaher IR — nongaap_2026Q3 ↗ |
Cite this data
StockData. (2026). Danaher Cepheid Respiratory Testing Revenue ($M), annual FY2025–FY2025 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/cepheid-respiratory-rev
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.